Background: The PRO-RBDD is a 3-year prospective data collection. Aims: It aims at understanding the association of FXIII activity and clinical severity in patients with FXIII deficiency. Benefits and complications of on-demand and prophylactic treatment were also evaluated. Methods: Data were collected at baseline (historical) and every 6 months (follow-up). 56 patients (31 females, 25 males), of whom 8 children (≤ 12 years) were recorded Results: Regression analysis confirmed a strong association between FXIII levels and age of diagnosis (Pearson test P < 0.05) or clinical severity (classified according to Peyvandi et al, JTH 2012) (b = 12.95, P < 0.05). Grade III bleeding were observed in 87% (20/23) and 67% (8/12) of patients with severe (undetectable activity) and moderate (5–30%) deficiency. More than 1/3 of patients with mild (> 30%) deficiency were asymptomatic and none did have grade III bleeding. Mucocutaneous bleedings, hematoma and haemarthrosis were present in almost 1/3 of patients, regardless their FXIII coagulant levels. More severe symptoms such as CNS, GI and umbilical cord bleeding were observed only in severe and moderate deficiency (13, 4 and 20%). Prophylaxis regimen with plasma-derived FXIII concentrates was used in 2/3 of severe patients and 1/3 of moderates. On 27 women, only 2 had menorrhagia; on 50 pregnancies, 25 ended to a spontaneous abortionand 5 showed bleeding complication. Follow-up data (up to 700 days) on 31 patients on “on-demand” therapy and on 18 on prophylaxis (9–57 U/Kg/month FXIII concentrate) showed an incidence bleeding rate of 1.8 patient-year 1 (95%CI 1.3–2.3) and 0.15 (95%CI 0.02–0.36), respectively. The risk of bleeding requiring replacement therapy is significantly higher in patient on “on-demand” (log rank test = 0.05). No thrombotic events were observed. Conclusion: The PRO-RBDD clearly confirmed the beneficial role of FXIII prophylaxis with no bleeding and no thrombotic events, making this treatment strongly recommended.
Factor XIII deficiency : preliminary results of the PRO-RBDD project / F. Peyvandi, R. Palla, M. Menegatti, S. Siboni, M. Boscarino, B. Lachmann, S. Halimeh, N. Fatima, M. Borhany, N. Ozdemir, M. Saracevic, D. Mikovic, A. Harvey, A. Mumford, F. Hsu, J. Chapin, H. Pergantou, H. Platokouki, A. Yilmaz, A. Williamson, A. Shapiro, A. Casini, P. de Moerloose, J. Payne, L. Muszbek. - In: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. - ISSN 1538-7836. - 13:suppl. 2(2015), pp. 940-940. (Intervento presentato al 25. convegno Congress of the International Society on Thrombosis and Haemostasis tenutosi a Toronto nel 2015).
Factor XIII deficiency : preliminary results of the PRO-RBDD project
F. Peyvandi;R. Palla;M. Menegatti;S. Siboni;
2015
Abstract
Background: The PRO-RBDD is a 3-year prospective data collection. Aims: It aims at understanding the association of FXIII activity and clinical severity in patients with FXIII deficiency. Benefits and complications of on-demand and prophylactic treatment were also evaluated. Methods: Data were collected at baseline (historical) and every 6 months (follow-up). 56 patients (31 females, 25 males), of whom 8 children (≤ 12 years) were recorded Results: Regression analysis confirmed a strong association between FXIII levels and age of diagnosis (Pearson test P < 0.05) or clinical severity (classified according to Peyvandi et al, JTH 2012) (b = 12.95, P < 0.05). Grade III bleeding were observed in 87% (20/23) and 67% (8/12) of patients with severe (undetectable activity) and moderate (5–30%) deficiency. More than 1/3 of patients with mild (> 30%) deficiency were asymptomatic and none did have grade III bleeding. Mucocutaneous bleedings, hematoma and haemarthrosis were present in almost 1/3 of patients, regardless their FXIII coagulant levels. More severe symptoms such as CNS, GI and umbilical cord bleeding were observed only in severe and moderate deficiency (13, 4 and 20%). Prophylaxis regimen with plasma-derived FXIII concentrates was used in 2/3 of severe patients and 1/3 of moderates. On 27 women, only 2 had menorrhagia; on 50 pregnancies, 25 ended to a spontaneous abortionand 5 showed bleeding complication. Follow-up data (up to 700 days) on 31 patients on “on-demand” therapy and on 18 on prophylaxis (9–57 U/Kg/month FXIII concentrate) showed an incidence bleeding rate of 1.8 patient-year 1 (95%CI 1.3–2.3) and 0.15 (95%CI 0.02–0.36), respectively. The risk of bleeding requiring replacement therapy is significantly higher in patient on “on-demand” (log rank test = 0.05). No thrombotic events were observed. Conclusion: The PRO-RBDD clearly confirmed the beneficial role of FXIII prophylaxis with no bleeding and no thrombotic events, making this treatment strongly recommended.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jth.12993.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
8 MB
Formato
Adobe PDF
|
8 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
